Insilico Medicine Successfully Delivered Milestone in Collaboration with Therasid Bioscience for AI-Driven MASH Therapeutics (IMAGE)
Caption
Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently achieved preclinical milestone in its collaboration with Therasid Bioscience, a South Korean based biotechnology company focuses on developing innovative first-in-class drugs for treatment for metabolic dysfunction-associated steatohepatitis (MASH).
MASH is a leading cause of chronic liver disease and a significant driver of liver cirrhosis and hepatic cellular carcinoma, impacting approximately 5% of adults worldwide. Despite its widespread prevalence and serious complications, there are currently no globally approved pharmacological therapies specifically targeting MASH.
In this collaboration, Insilico successfully optimized a series of compounds provided by Therasid Bioscience targeting a challenge protein, with a focus on improving ADMET properties. By leveraging its proprietary AI-powered generative chemistry engine, Chemistry42, Insilico's team synthesized and tested approximately 40 molecules within only 4 months, ultimately identifying candidate compounds with highly satisfactory properties.
Moving forward, the molecule will undergo further development by Therasid Bioscience, including in vivo and in vitro validation. These efforts will pave the way for the molecule to be nominated as the preclinical candidate, laying a solid foundation for future therapeutic innovation to address this critical unmet medical need.
Credit
Insilico Medicine
Usage Restrictions
None
License
Original content